Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

BACKGROUND: Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune checkpoint inhibitors. While the molecular heterogeneity...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Loupakis, Fotios, Maddalena, Giulia, Depetris, Ilaria, Murgioni, Sabina, Bergamo, Francesca, Dei Tos, Angelo Paolo, Rugge, Massimo, Munari, Giada, Nguyen, Andrew, Szeto, Christopher, Zagonel, Vittorina, Lonardi, Sara, Fassan, Matteo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842181/
https://ncbi.nlm.nih.gov/pubmed/31703605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0788-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller